Nanobiotix S.A.
NBTX
$28.23
-$2.08-6.86%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -79.54% | -107.83% | -138.66% | -20.08% | -- |
| Total Other Revenue | -49.47% | -39.50% | -28.14% | -18.13% | -8.27% |
| Total Revenue | -75.28% | -97.24% | -119.90% | -19.50% | 547.32% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -75.28% | -97.24% | -119.90% | -19.50% | 547.32% |
| SG&A Expenses | -4.02% | -6.83% | -6.94% | 4.63% | 18.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.80% | -8.82% | 1.03% | 12.26% | 25.70% |
| Operating Income | -96.52% | -139.33% | -182.02% | -31.99% | 50.15% |
| Income Before Tax | -55.94% | -63.61% | -72.05% | -5.43% | 41.58% |
| Income Tax Expenses | -114.13% | -83.44% | -15.94% | 183.16% | 3,822.22% |
| Earnings from Continuing Operations | -54.61% | -62.85% | -71.79% | -5.67% | 41.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.61% | -62.85% | -71.79% | -5.67% | 41.13% |
| EBIT | -96.52% | -139.33% | -182.02% | -31.99% | 50.15% |
| EBITDA | -103.55% | -146.75% | -189.65% | -35.43% | 50.68% |
| EPS Basic | -43.07% | -34.99% | -30.94% | 18.95% | 53.14% |
| Normalized Basic EPS | -88.30% | -73.93% | -66.63% | 8.78% | 57.47% |
| EPS Diluted | -42.18% | -34.33% | -30.40% | 18.82% | 52.73% |
| Normalized Diluted EPS | -88.30% | -73.93% | -66.63% | 8.78% | 57.47% |
| Average Basic Shares Outstanding | 10.33% | 18.50% | 27.99% | 25.59% | 23.04% |
| Average Diluted Shares Outstanding | 10.33% | 18.50% | 27.99% | 25.59% | 23.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |